Rimegepant(CAS: 1289023-67-1)

Rimegepant is a selective calcitonin gene-related peptide receptor antagonist. It is available as a crystalline compound with a molecular weight of approximately 425.47 g/mol. Rimegepant has a solubility of about 2.2 mg/mL in water and is practically insoluble in organic solvents like ethanol and chloroform. Its chemical reactivity is low under normal conditions, but it is susceptible to degradation under acidic or alkaline conditions.

Rimegepant is synthesized through a multi-step process involving peptide coupling and protection/deprotection steps. The key synthetic route involves the formation of a protected peptide, followed by deprotection, coupling, and final purification. This process involves the use of various catalysts and reagents, ensuring high yield and selectivity.

Rimegepant is primarily used in the pharmaceutical industry, specifically for the prevention of migraines. It is also relevant in the research and development of other peptide-based drugs. While not commonly used in other industries due to its specific application, it may be of interest in advanced chemistry and pharmaceutical research.

When handling Rimegepant, it is essential to use appropriate personal protective equipment (PPE), such as gloves and safety glasses, and to work in a well-ventilated area or fume hood. Spills should be cleaned up immediately using appropriate absorbent materials and disposing of them according to hazardous waste regulations. Always refer to the Safety Data Sheet (SDS) for specific handling and disposal instructions.